@article{f8fef5e6ee8f4c6cad830ca549273e1c,
title = "Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction",
abstract = "The protein tau and its isoforms are associated with several neurodegenerative diseases, many of which are characterized by greater deposition of the 4-repeat (4R) tau isoform; however, the role of 4R tau in disease pathogenesis remains unclear. We created antisense oligonucleotides (ASOs) that alter the ratio of 3R to 4R tau to investigate the role of specific tau isoforms in disease. Preferential expression of 4R tau in human tau-expressing (hTau-expressing) mice was previously shown to increase seizure severity and phosphorylated tau deposition without neuronal or synaptic loss. In this study, we observed strong colocalization of 4R tau within reactive astrocytes and increased expression of pan-reactive and neurotoxic genes following 3R to 4R tau splicing ASO treatment in hTau mice. Increasing 4R tau levels in primary astrocytes provoked a similar response, including a neurotoxic genetic profile and diminished homeostatic function, which was replicated in human induced pluripotent stem cell-derived (iPSC-derived) astrocytes harboring a mutation that exhibits greater 4R tau. Healthy neurons cultured with 4R tau-expressing human iPSC-derived astrocytes exhibited a higher firing frequency and hypersynchrony, which could be prevented by lowering tau expression. These findings support a potentially novel pathway by which astrocytic 4R tau mediates reactivity and dysfunction and suggest that astrocyte-targeted therapeutics against 4R tau may mitigate neurodegenerative disease progression.",
author = "Ezerskiy, {Lubov A.} and Schoch, {Kathleen M.} and Chihiro Sato and Mariana Beltcheva and Kanta Horie and Frank Rigo and Ryan Martynowicz and Karch, {Celeste M.} and Bateman, {Randall J.} and Miller, {Timothy M.}",
note = "Funding Information: This study was supported by the Rainwater Charitable Foundation (TMM, CMK, and RJB), NIH NS110890 (CMK), and NIH/National Institute on Aging K01AG062796 (CS). We would also like to thank the Human Cells, Tissues and Organoids Core at Washington University in St. Louis for all iAstro-cyte differentiation and culture. ASOs used in these experiments were provided by Ionis Pharmaceuticals. TMM is an inventor on patent/patent application PCT/US2013/031500, nationalized to US Issued Patent 10,273,474 (with corresponding national stage applications or issued patents in Australia, Canada, Europe, and Japan), and on continuation or divisional patent applications (US patent application number 16/298,607 and Australia Issued Patent 2016202220) regarding use of tau ASOs in neurodegenerative syndrome. Washington University jointly owns this patent family with Ionis Pharmaceuticals. Microscopy was performed through the use of Washington University Center for Cellular Imaging supported by Washington University School of Medicine, The Children{\textquoteright}s Discovery Institute of Washington University and St. Louis Children{\textquoteright}s Hospital (CDI-CORE-2015-505 and CDI-CORE-2019-813), and the Foundation for Barnes-Jewish Hospital (3770 and 4642). Publisher Copyright: {\textcopyright} 2022, Ezerskiy et al.",
year = "2022",
month = jan,
day = "11",
doi = "10.1172/jci.insight.152012",
language = "English",
volume = "7",
journal = "JCI insight",
issn = "2379-3708",
number = "1",
}